Switching from IV to oral antibiotics for staph bloodstream infection
Part of Infections clinical trials.
This trial tests whether switching from IV antibiotics to oral antibiotics after 3–7 days is safe and effective for people with uncomplicated Staphylococcus aureus bloodstream infections. It may help you avoid a longer hospital stay and reduce IV-related complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed Staphylococcus aureus bloodstream infection.
- You have received 3 to 7 days of the right IV antibiotics and the infection is cleared (negative blood culture).
- You have been fever-free for 2 days.
- You do not have signs of infection spreading to other parts of the body (like heart, bones, or organs).
- You do not have severe kidney disease, severe liver disease, or a weakened immune system.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the best treatment approach for bloodstream infections caused by Staphylococcus aureus (“S. aureus”). It uses a flexible design to decide which treatment track you fit into, and may help improve recovery while avoiding unnecessary medications.
This study tests different combinations of antibiotics to treat a staph infection in the blood. If you're in an Intermountain hospital with this infection, the trial may help doctors find the most effective treatment for you.
This study looks at whether giving two antibiotics early for a serious staph infection in the blood leads to better results than the standard one antibiotic. It uses existing hospital monitoring and follow-up visits to track progress.
This Phase 2 study tests whether adding ertapenem to cefazolin can improve treatment of staphylococcus (“S. aureus”) bloodstream infection that is likely methicillin-susceptible (MSSA). It aims to start the right antibiotics quickly, before MRSA status is fully confirmed, using early testing and a treatment plan guided by infectious-disease specialists.
This trial compares two antibiotics, vancomycin and daptomycin, to see which works better for treating MRSA bacteria in the blood. Patients are randomly assigned to one of the drugs and will be monitored closely for results and side effects.
This trial tests whether switching from IV to oral antibiotics is just as effective for treating Gram-negative bloodstream infections. If you qualify, you may receive either continued IV antibiotics or switch to pills, with follow-up on your recovery and quality of life.
Hear when a new Staphylococcus Aureus Bacteremia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.